FDA approves Jascayd for progressive pulmonary fibrosis
by Lori Solomon edited by Stephanie Baum, reviewed by Andrew Zinin Editors’ notes The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. Jascayd becomes the first and only preferential phosphodiesterase 4B inhibitor with immunomodulatory and antifibrotic effects approved for this indication. The approval is based on results from […]
FDA approves Jascayd for progressive pulmonary fibrosis Read More »
